In the present study, using a novel disease model of lung cancer with IP and a human cohort, we demonstrated that the HIF-1 pathway plays a critical role in IP-mediated lung cancer progression and can thus serve as a therapeutic target. This evidence concerns the gene HIF1A and incontinentia pigmenti.